Om bidragsyterne

UCB Pharma, Inc., Rochester, New York. He is responsible for developing IEDS technology, which is used to formulate extended release suspensions. During his fifteen-year career, he has led the development of several marketed extended release products and has published numerous scientific articles in the field of oral and transdermal drug delivery systems. Dr. Thassu holds several US and European patents and received the M. Pharm. degree in pharmaceutics (1986) from Saugor University, India, the Ph.D. degree in pharmaceutical sciences (1991) from the University of Cincinnati, Ohio, and the MBA degree (2007) from Cornell University, Ithaca, New York. MICHEL DELEERS is Vice President, Global Pharmaceutical Technology and Analytical Development and Clinical Supplies for UCB Pharma, Chemin du Foriest, Braine l’Alleud, Belgium, responsible for developing products with new drug delivery systems, new nano and microparticulate systems, and alternative routes of adminstration for insoluble and biological drugs. He received the Ph.D. degree in chemical sciences (1978) and the D.Sc. degree (1986) from the Université Libre de Bruxelles, Belgium. A member of the Royal Chemical Society of Belgium, the International Pharmaceutical Federation (FIP), and the American Association of Pharmaceutical Scientists (AAPS), Dr. Deleers has published more than 125 scientific articles and has obtained 20 patents. YASHWANT PATHAK is currently Director, Research and Development for PharmaFab, Grand Prairie, Texas, a company providing contract research services for specialized drug delivery systems. The author of over 100 research publications, including several papers on sub-micronized emulsions and PLA: PLGA nano-particles, he began his career as a Lecturer in pharmaceutics at Delhi University, New Delhi, India. Dr. Pathak received the Ph.D. degree from Nagpur University, India and was awarded a fellowship from the American Heart Association to complete research on cardiovascular drug delivery systems.